Jazz Pharmaceuticals plc (JAZZ)
JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View
Jazz Pharmaceuticals posts strong Q3 results with higher EPS and sales, aided by a tax benefit and robust neuroscience growth.
Jazz Pharmaceuticals plc (JAZZ) Q3 2025 Earnings Call Transcript
Jazz Pharmaceuticals plc ( JAZZ ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Jack Spinks - Executive Director of Investor Relations Renée Galá - President, CEO & Director Samantha Pearce - Executive VP & Chief Commercial Officer Robert Iannone - Executive VP, Chief Medical Officer and Global Head of Research & Development Philip Johnson - Executive VP & CFO Conference Call Participants Marc Goodman - Leerink Partners LLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Akash Tewari - Jefferies LLC, Research Division Jason Gerberry - BofA Securities, Research Division Ami Fadia - Needham & Company, LLC, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division David Hoang - Deutsche Bank AG, Research Division Ashwani Verma - UBS Investment Bank, Research Division Joseph Thome - TD Cowen, Research Division Asim Rana - Truist Securities, Inc., Research Division Michael Riad - Morgan Stanley, Research Division Denis Reznik - Raymond James & Associates, Inc., Research Division Presentation Operator Good day, and thank you for standing by.
Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Beat Estimates
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $8.13 per share, beating the Zacks Consensus Estimate of $5.74 per share. This compares to earnings of $6.61 per share a year ago.
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Pharmaceuticals Plc (JAZZ) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 9:30 AM EDT Company Participants Amal Melhem-Bertrandt Philip Johnson - Executive VP & CFO Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Thank you very much for joining us today. My name is Mohit Bansal.
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.
Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock
Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut
Jazz shares slide as Q2 loss widens on Chimerix charge, with 2025 sales outlook trimmed despite higher EPS guidance.
Jazz Pharmaceuticals plc (JAZZ) Q2 2025 Earnings Call Transcript
Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Bruce C. Cozadd - Co-Founder, Chairman & CEO Jack Spinks - Corporate Participant Philip L.
Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates
Jazz Pharmaceuticals (JAZZ) came out with a quarterly loss of $8.25 per share versus the Zacks Consensus Estimate of a loss of $6.12. This compares to earnings of $5.3 per share a year ago.
